NASDAQ:XAIR

Beyond Air Stock Forecast, Price & News

$8.00
-0.21 (-2.56 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.89
$8.19
50-Day Range
$4.72
$8.40
52-Week Range
$4.62
$9.30
Volume283,639 shs
Average Volume651,276 shs
Market Capitalization$175.20 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.53
30 days | 90 days | 365 days | Advanced Chart
Receive XAIR News and Ratings via Email

Sign-up to receive the latest news and ratings for Beyond Air and its competitors with MarketBeat's FREE daily newsletter.


Beyond Air logo

About Beyond Air

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

105th out of 2,214 stocks

Surgical & Medical Instruments Industry

11th out of 181 stocks

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Beyond Air (NASDAQ:XAIR) Frequently Asked Questions

Is Beyond Air a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyond Air in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Beyond Air stock.
View analyst ratings for Beyond Air
or view top-rated stocks.

What stocks does MarketBeat like better than Beyond Air?

Wall Street analysts have given Beyond Air a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Beyond Air wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Beyond Air?

Beyond Air saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 2,640,000 shares, a decrease of 29.2% from the June 15th total of 3,730,000 shares. Based on an average trading volume of 462,900 shares, the days-to-cover ratio is presently 5.7 days. Currently, 14.6% of the shares of the stock are short sold.
View Beyond Air's Short Interest
.

When is Beyond Air's next earnings date?

Beyond Air is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Beyond Air
.

How can I listen to Beyond Air's earnings call?

Beyond Air will be holding an earnings conference call on Tuesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Beyond Air's earnings last quarter?

Beyond Air, Inc. (NASDAQ:XAIR) issued its earnings results on Wednesday, June, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.07. The company earned $0.15 million during the quarter, compared to the consensus estimate of $0.38 million. Beyond Air had a negative net margin of 2,617.28% and a negative trailing twelve-month return on equity of 111.52%.
View Beyond Air's earnings history
.

How has Beyond Air's stock been impacted by Coronavirus (COVID-19)?

Beyond Air's stock was trading at $5.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XAIR stock has increased by 50.4% and is now trading at $8.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XAIR?

5 Wall Street analysts have issued 1-year price objectives for Beyond Air's stock. Their forecasts range from $9.00 to $17.00. On average, they anticipate Beyond Air's stock price to reach $12.20 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for Beyond Air
or view top-rated stocks among Wall Street analysts.

Who are Beyond Air's key executives?

Beyond Air's management team includes the following people:
  • Mr. Steven Adam Lisi, CEO & Chairman (Age 50, Pay $450k)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 47, Pay $400k)
  • Mr. Douglas J. Beck CPA, CPA, Chief Financial Officer (Age 60, Pay $250k)
  • Mr. Adam Newman, Chief Legal Officer & Gen. Counsel
  • Mr. Duncan Fatkin, Chief Commercial Officer
  • Ms. Maria Yonkoski, Head of Investor Relations
  • Ms. Rebecca Van Doren, Head of Sales
  • Ms. Kori-Ann Taylor, Head of Marketing
  • Dr. Giora Davidai M.D., Chief Medical Officer
  • Mr. Ali Ardakani, Sr. VP of Device & Bus. Devel.

Who are some of Beyond Air's key competitors?

What other stocks do shareholders of Beyond Air own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyond Air investors own include OPKO Health (OPK), NVIDIA (NVDA), Pfizer (PFE), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Enphase Energy (ENPH), General Motors (GM), Livongo Health (LVGO), Main Street Capital (MAIN) and Ollie's Bargain Outlet (OLLI).

What is Beyond Air's stock symbol?

Beyond Air trades on the NASDAQ under the ticker symbol "XAIR."

How do I buy shares of Beyond Air?

Shares of XAIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beyond Air's stock price today?

One share of XAIR stock can currently be purchased for approximately $8.00.

How much money does Beyond Air make?

Beyond Air has a market capitalization of $175.20 million and generates $870,000.00 in revenue each year. The company earns $-22,880,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Beyond Air have?

Beyond Air employs 41 workers across the globe.

What is Beyond Air's official website?

The official website for Beyond Air is www.ait-pharm.com.

Where are Beyond Air's headquarters?

Beyond Air is headquartered at 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530.

How can I contact Beyond Air?

Beyond Air's mailing address is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. The company can be reached via phone at 516-665-8200.


This page was last updated on 7/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.